- Results from a Phase 3 clinical trial, ATHOS-3, evaluating La Jolla Pharmaceutical's (NASDAQ:LJPC) GIAPREZA (angiotensin II) in patients with high output vasodilatory shock showed a treatment benefit. The results are being presented at the Society of Critical Care Medicine's 47th Critical Care Congress in San Antonio, TX.
- Patients with APACHE II scores >30 (ICU mortality score) and baseline MAP < 65 mmHg (very low mean arterial pressure) receiving GIAPREZA experienced a mortality rate at day 28 of 51.8% (n=30/58) compared to 70.8% (n=46/65) for placebo (p=0.037).
- The treatment effect from GIAPREZA in patients with MAP < 65 mmHg was also greater than placebo (28-day mortality 54.2% vs. 70.4%, respectively), but the separation fell short of statistical significance (p=0.10).
- The FDA approved GIAPREZA for the treatment of adults with septic shock or other distributive shock in December 2017.
- Previously: La Jolla's LJPC-501 achieves primary endpoint in late-stage study in patients with life-threatening drop in blood pressure; shares down 10% premarket on disappointing effect on mortality (May 22, 2017)
- Now read: Daily Insider Ratings Round Up 2/20/18: BH, DM, LGCY, LJPC, MCHX, SNAP, ZBH
Original article